The European Commission and European Medicines Agency have approved the triple combination Kaftrio for use in certain cystic fibrosis patients, triggering the drug to be accessible on the UK’s National Health Service.
List view / Grid view
Filter the results
The European Commission has approved the label extension for KALYDECO® (ivacaftor) to include the treatment of infants with cystic fibrosis between six and 12 months old.
A new agreement will allow eligible cystic fibrosis patients in England to have access to CFTR modulators to treat the underlying cause of their disease.
Vertex Pharmaceuticals has reached an agreement with ROI to fund Orkambi for all of the approximately 500 people in Ireland with cystic fibrosis...
The Scottish Medicines Consortium (SMC) has rejected Kalydeco (ivacaftor) and Orkambi (lumacaftor-ivacaftor) for the treatment of cystic fibrosis.